CN Patent

CN118286440A — 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合

Assigned to Merck Sharp and Dohme BV · Expires 2024-07-05 · 2y expired

What this patent protects

本发明阐述包含程序性死亡1受体(PD‑1)拮抗剂及VEGFR抑制剂的组合疗法及该组合疗法的用途，其用于治疗癌症，且具体而言用于治疗表达PD‑L1的癌症。

USPTO Abstract

本发明阐述包含程序性死亡1受体(PD‑1)拮抗剂及VEGFR抑制剂的组合疗法及该组合疗法的用途，其用于治疗癌症，且具体而言用于治疗表达PD‑L1的癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN118286440A
Jurisdiction
CN
Classification
—
Expires
2024-07-05
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.